Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SRZN vs CNTB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (33.2 SELL vs 41.0 SELL), While CNTB Leads 4–1 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: SRZN 1 – 4 CNTB (1 Tie) Matrix Metrics: SRZN 5 – 4 CNTB

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (33.2/100 SELL vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. SRZN trades at $29.93 (N/M Forward P/E, -485.4% operating margin) versus CNTB at $0.59 (0.8x Forward P/E, -2384.5% operating margin).

  • Composite vs. Pillar Nuance: While CNTB currently prints a higher short-term Unified Composite Score (41.0/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -2384.5% operating margin) and revenue trajectory (+408.6% vs. +5666.7% YoY).
  • Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (33.2/100 SELL) and CNTB (41.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs CNTB
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 66% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28
CNTB NASDAQ
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.59
-7.94% 1D
Market Cap $42.6M
TTM Revenue $3.0M
Forward P/E 0.8x
Beta / 30D Vol 0.92β · 68% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.7%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.75 · SMA50: $0.99

6-Pillar Scorecard Institutional Category Breakdown (SRZN 1 – 4 CNTB)

Columns: Metric · SRZN · CNTB
1. Valuation Multiples CNTB
Forward P/E N/M 0.8x
Trailing P/E N/M 0.8x
PEG Ratio N/M N/M
EV / Revenue 48.3x 5.5x
2. Growth & Scale CNTB
Revenue Growth (YoY) +408.6% +5666.7%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $3.0M
Market Cap $602.5M $42.6M
3. Profitability & Quality SRZN
Gross Margin N/A 100.0%
Operating Margin -485.4% -2384.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -140.5%
4. Balance Sheet & Cash Flow CNTB
Cash Generation (TTM) -$31M -$61M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNTB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) 397.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs CNTB (4)
Institutional Metric SRZN CNTB Criterion Row Edge
Market Capitalization
Scale
$602.5M $42.6M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 0.8x Lower Multiple CNTB
Forward P/E Ratio
Valuation
N/M 0.8x Lower Multiple CNTB
Revenue Growth (YoY)
Growth
+408.6% +5666.7% Higher Growth CNTB
Operating Margin (TTM)
Profitability
-485.4% -2384.5% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -140.5% Higher ROE SRZN
52-Week Range Position
Momentum
69% ($12–$38) 1% ($1–$4) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.28β · 66% Vol 0.92β · 68% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
33.2 / 100 (SELL) 41.0 / 100 (SELL) Higher Composite CNTB
Trailing 12M Revenue (USD)
Operating Scale
$11M $3.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · 5.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$61M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +59.79 pp
SRZN: +25.57% · CNTB: -34.22%
3M Horizon SRZN +100.62 pp
SRZN: +24.68% · CNTB: -75.94%
6M Horizon SRZN +90.04 pp
SRZN: +17.07% · CNTB: -72.97%
1Y Horizon SRZN +202.7 pp
SRZN: +130.62% · CNTB: -72.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue CNTB Revenue SRZN Op. Margin CNTB Op. Margin Margin Leader
FY2022 $10M N/A -354.7% N/A SRZN
FY2024 $10M $30M -239.7% -86.2% CNTB
FY2025 $0M $0M -1210.6% -90740.6% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNTB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 397.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNTB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs CNTB Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (33.2/100 SELL vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. SRZN trades at $29.93 (N/M Forward P/E, -485.4% operating margin) versus CNTB at $0.59 (0.8x Forward P/E, -2384.5% operating margin). Composite vs. Pillar Nuance: While CNTB currently prints a higher short-term Unified Composite Score (41.0/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -2384.5% operating margin) and revenue trajectory (+408.6% vs. +5666.7% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (33.2/100 SELL) and CNTB (41.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile CNTB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNTB leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with CNTB at +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), SRZN cumulative revenue shifted +0.0% while CNTB shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNTB.

CNTB screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus CNTB (-140.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk). By comparison, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.